Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Spatial, temporal, and molecular heterogeneity of ADC targets in high-grade serous ovarian carcinoma.

British journal of cancer - 1 Sept 2026

Li Xiaoxuan, Janik Tobias, Möbs Markus, Florian Stefan, Schmitt Wolfgang D, Dzakulic Amra, Sehouli Jalid, Horst David, Dubois Frank P B, Braicu Elena Ioana, Dragomir Mihnea P

Abstract excerpt

BACKGROUND: Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for high-grade serous ovarian carcinoma (HGSOC). Patient selection for ADC therapy depends on tumour target expression, making it essential to characterize molecular, spatial, and temporal heterogeneity. METHODS: We analyzed two HGSOC tissue microarray cohorts: 100 genomically profiled cases (1565 cores) and 64 matched cases...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to Cell Adhesion Molecules

Share to Cystadenocarcinoma, Serous

Share to Neoplasm Grading

Share to Ovarian Neoplasms

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 42231029
DOI: 10.1038/s41416-026-03482-2
PMCID: PMC13478159

Genes

BRCA1
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Spatial, temporal, and molecular heterogeneity of ADC targets in high-grade serous ovarian carcinoma.PMID 42231029Read ↗

Spatial, Temporal, and Molecular Heterogeneity of ADC targets in High-Grade Serous Ovarian CarcinomaSemantic proximity Read ↗

Multi-Omic Profiling Reveals Antibody-Drug Conjugate Targetability in Ovarian CancerSemantic proximity Read ↗

The mutational landscape defines the proteome and spatial organization of tumor, stroma and immune cells in ovarian cancerSemantic proximity Read ↗

Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma.Semantic proximity Read ↗

Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatmentSemantic proximity Read ↗

Folate receptor alpha protein expression in ovarian serous cystadenocarcinoma tumors of The Cancer Genome Atlas: exploration beyond single-agent therapySemantic proximity Read ↗

Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.Semantic proximity Read ↗

Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinomaSemantic proximity Read ↗

Ovarian cancer mutational processes drive site-specific immune evasion.Semantic proximity Read ↗

Phenotypic and genotypic characterization of single circulating tumor cells in the follow-up of high-grade serous ovarian cancer.Semantic proximity Read ↗

RB1 expression and HR proficiency define a poor-outcome molecular subtype of high grade serous ovarian carcinomaSemantic proximity Read ↗

Homologous recombination deficiency and Cyclin E1 amplification are correlated with immune cell infiltration and survival in high-grade serous ovarian cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.